z-logo
open-access-imgOpen Access
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Author(s) -
Peter Bergman,
Ola Blennow,
Lotta Hansson,
Stephan Mielke,
Piotr Nowak,
Puran Chen,
Gunnar Söderdahl,
Anders Österborg,
Smith Rjh,
David Wullimann,
Jan Vesterbacka,
Gustaf Lindgren,
Lisa Blixt,
Gustav Friman,
Emilie Wahren-Borgström,
Anordlander,
Angélica Cuapio,
Mira Akber,
Davide Valentini,
Anna-Carin Norlin,
Anders Thalme,
Gordana Bogdanović,
Sandra Muschiol,
Peter Nilsson,
Sophia Hober,
Karin Loré,
Margaret Chen,
Marcus Buggert,
HansGustaf Ljunggren,
Per Ljungman,
Soo Aleman
Publication year - 2021
Publication title -
ebiomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.596
H-Index - 63
ISSN - 2352-3964
DOI - 10.1016/j.ebiom.2021.103705
Subject(s) - covid-19 , medicine , clinical trial , open label , virology , immunology , outbreak , disease , infectious disease (medical specialty)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom